You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer

Article metrics

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer

 

Online download statistics by month:

Online download statistics by month: February 2020 to January 2026

AbstractFullPdf
Feb 2020312312161
Mar 202023023076
Apr 2020148148101
May 2020555564
Jun 2020565630
Jul 2020707021
Aug 2020454530
Sep 2020767623
Oct 2020555535
Nov 2020666639
Dec 2020797931
Jan 2021969640
Feb 202111511567
Mar 202110910965
Apr 2021696929
May 2021717146
Jun 2021535334
Jul 2021505032
Aug 2021727243
Sep 2021828254
Oct 2021616151
Nov 2021858555
Dec 2021656526
Jan 2022868948
Feb 20229110749
Mar 202222022253
Apr 202210110943
May 202210411149
Jun 202212713053
Jul 2022939631
Aug 202210210673
Sep 202211111459
Oct 202212012878
Nov 202210911361
Dec 2022919235
Jan 2023939540
Feb 202311311329
Mar 202313314073
Apr 2023939443
May 2023919123
Jun 202315816248
Jul 202311811837
Aug 2023889029
Sep 202312412641
Oct 202315415541
Nov 2023989827
Dec 202310010029
Jan 2024848546
Feb 2024888943
Mar 2024144145103
Apr 202411611763
May 2024989850
Jun 2024949446
Jul 202420320532
Aug 202419219431
Sep 202414014052
Oct 202417617659
Nov 202418618756
Dec 202420120640
Jan 202518719144
Feb 202527427459
Mar 202520520751
Apr 202523223447
May 202513614145
Jun 202515215339
Jan 2026330
Total774978583151